Stemline Therapeutics CEO Ivan Bergstein's 2018 pay jumps 177% to $9.4M
Stemline Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 30, 2019
Stemline Therapeutics reported fiscal year 2018 executive compensation information on April 30, 2019.
In 2018, three executives at Stemline Therapeutics received on average a compensation package of $6.4M, a 199% increase compared to previous year.
Average pay of disclosed executives at Stemline Therapeutics
Ivan Bergstein, Chief Executive Officer, received $9.4M in total, which increased by 177% compared to 2017. 84% of Bergstein's compensation, or $7.9M, was in stock awards. Bergstein also received $674K in bonus, $278K in non-equity incentive plan, as well as $599K in salary.
Kenneth Hoberman, Chief Operating Officer, received a compensation package of $7.5M, which increased by 303% compared to previous year. 77% of the compensation package, or $5.8M, was in stock awards.
David Gionco, Chief Accounting Officer, earned $2.1M in 2018, a 93% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 30, 2019.